A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Injections of HRS-5817 Injection in Healthy Adult Volunteers With or Without Obesity
Latest Information Update: 25 Nov 2025
At a glance
- Drugs HRS 5817 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Fujian Shengdi Pharmaceutical
Most Recent Events
- 25 Nov 2025 New trial record